Taysha Gene Therapies Quarterly Cash Flow Statement
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
4.49+0.06 (+1.35%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies free cash flow
In the quarter ended Jun 30, 2026, Taysha Gene Therapies generated -$40.4 million of operating cash flow and spent $1,000 on capital expenditures. That left free cash flow of -$40.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -46.64M | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M | -18.79M | -25.52M | -20.93M | -24.06M | 47.74M | -117.09M |
| Net Income growth (YoY) | — | — | — | — | — | — | -139.35% | — | — | — | — | — |
| Depreciation & Amortization | 400.00K | 295.00K | 299.00K | 200.00K | 300.00K | 283.00K | 304.00K | 300.00K | 300.00K | 325.00K | 366.00K | 300.00K |
| Stock-Based Compensation | 5.81M | 5.55M | 3.53M | 3.29M | 3.19M | 3.29M | 3.22M | 3.36M | 3.33M | 3.20M | 1.97M | 2.04M |
| Change in Working Capital | 3.91M | 495.00K | -9.75M | -977.00K | 1.49M | -2.43M | -2.71M | -6.31M | -1.91M | -124.00K | -2.83M | -4.43M |
| Operating Cash Flow | -40.42M | -40.88M | -26.72M | -24.17M | -20.18M | -22.02M | -18.31M | -21.61M | -21.50M | -19.80M | -16.12M | -17.95M |
| Capital Expenditures | 1.00K | -24.00K | -250.00K | -108.00K | -2.00K | -378.00K | 2.00K | -35.00K | -201.00K | -140.00K | -17.00K | 0 |
| Investing Cash Flow | 1.00K | -3.02M | -247.00K | -48.00K | 62.00K | -371.00K | 13.00K | -35.00K | -201.00K | -140.00K | -10.00K | -3.49M |
| Financing Cash Flow | 216.66M | 711.00K | 49.56M | 8.80M | 216.29M | -52.00K | -357.00K | 6.59M | 70.47M | -22.00K | -4.25M | 140.63M |
| Net Change in Cash | 176.23M | -43.19M | 22.59M | -15.42M | 196.17M | -22.44M | -18.65M | -15.05M | 48.76M | -19.96M | -20.38M | 119.19M |
| Free Cash Flow | -40.42M | -40.90M | -26.97M | -24.27M | -20.18M | -22.40M | -18.31M | -21.65M | -21.70M | -19.94M | -16.13M | -17.95M |
This table shows 12 quarterly periods of Taysha Gene Therapies's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a cash flow statement?